Article Text
PDF
Statistics from Altmetric.com
Components of Participating Organizations
National Institutes of Health
National Center for Advancing Translational Sciences
National Cancer Institute
National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of General Medical Sciences
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Application Receipt/Submission Date(s): Multiple dates, see announcement.
Funding Opportunity Purpose
The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects. The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.
Complete details available at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-088.html.
ALZHEIMER’S DISEASE PILOT CLINICAL TRIALS (R01): PAR-14-089
Components of Participating Organizations
National Institute on Aging
Application Receipt/Submission Date(s): Multiple dates, see announcement.
Funding Opportunity Purpose
The objective of the Alzheimer’s Disease Pilot Clinical Trials initiative is to enable the clinical testing (Phase I and II) of promising pharmacological and non-pharmacological interventions in individuals across the Alzheimer’s disease (AD) spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to …